ASH: More intense treatment beneficial in polycythemia vera

ASH: More intense treatment beneficial in polycythemia vera
For patients with polycythemia vera, more intense treatment to achieve a hematocrit target of less than 45 percent correlates with a significantly lower rate of cardiovascular death and major thrombosis compared with a target of 45 to 50 percent, according to a study published online Dec. 8 in the New England Journal of Medicine to coincide with presentation at the annual meeting of the American Society of Hematology, held from Dec. 8 to 11 in Atlanta.

(HealthDay)—For patients with polycythemia vera, more intense treatment to achieve a hematocrit target of less than 45 percent correlates with a significantly lower rate of cardiovascular death and major thrombosis compared with a target of 45 to 50 percent, according to a study published online Dec. 8 in the New England Journal of Medicine to coincide with presentation at the annual meeting of the American Society of Hematology, held from Dec. 8 to 11 in Atlanta.

Roberto Marchioli, M.D., from the Consorzio Mario Negri Sud in Santa Maria Imbaro, Italy, and colleagues conducted a involving 365 adults with JAK2-positive polycythemia vera to compare more intensive treatment (target hematocrit less than 45 percent; low-hematocrit group) or less intensive treatment (target hematocrit 45 to 50 percent; high-hematocrit group) with phlebotomy, , or both.

After a median follow-up of 31 months, the researchers found that the primary end point (time until death from cardiovascular causes or major thrombotic events) was reached by 2.7 percent of patients in the low-hematocrit group and 9.8 percent in the high-hematocrit group (hazard ratio in high-hematocrit group, 3.91). The primary end point plus superficial-vein thrombosis was reached by 4.4 and 10.9 percent, respectively (hazard ratio, 2.69). The rates of adverse events were similar between the groups.

"In conclusion, among patients with polycythemia vera, maintaining a hematocrit target of less than 45 percent, as compared with a target of 45 to 50 percent, was associated with a significantly lower rate of thrombotic complications without an increase in serious treatment complications," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

More information: Abstract
Full Text
Editorial
More Information

add to favorites email to friend print save as pdf

Related Stories

Early surgery ups outcomes in infective endocarditis

Jun 28, 2012

(HealthDay) -- For patients with infective endocarditis and large vegetations, early surgery reduces death from any cause and embolic events, compared with conventional treatment, according to a study published ...

How many cells can our blood tolerate?

Jun 14, 2012

Bioinformaticians of Jena University (Germany) have found out that the optimal value of hematocrit -- which indicates the volume fraction of the red blood cells -- can be calculated with an equation that dates ...

Recommended for you

Ebola discoverer says would sit next to victim on train

3 hours ago

The scientist who helped discover the Ebola virus said the outbreak in west Africa was unlikely to trigger a major epidemic outside the region, adding he would happily sit next to an infected person on a train.

Peace Corps withdraws from W. Africa over Ebola fears

3 hours ago

The US Peace Corps announced Wednesday it was pulling hundreds of volunteers from Guinea, Liberia and Sierra Leone due to growing concerns over the spread of the deadly Ebola epidemic raging in West Africa.

User comments